Novavax (NVAX) Other Accumulated Expenses (2013 - 2026)

Novavax's Other Accumulated Expenses history runs 14 years deep, the most recent figure standing at $132.4 million for Q1 2026.

• On a quarterly basis, Other Accumulated Expenses fell 6.75% year-over-year to $132.4 million in Q1 2026; TTM through Mar 2026 was $132.4 million, a 6.75% decrease from a year earlier, with the FY2025 full-year figure at $137.8 million, down 37.26% from the prior year.
• Other Accumulated Expenses fell to $132.4 million in Q1 2026 per NVAX's latest filing, from $137.8 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $930.1 million in Q4 2022 and bottomed at $31.3 million in Q1 2022.
• The 5-year median for Other Accumulated Expenses is $219.6 million (2024), against an average of $362.1 million.
• Across the five-year window, Other Accumulated Expenses soared 4312.95% in 2022 and plunged 74.51% in 2024, its largest moves.
• Year by year, Other Accumulated Expenses stood at $930.1 million in 2022, then dropped by 7.38% to $861.4 million in 2023, then sank by 74.51% to $219.6 million in 2024, then plunged by 37.26% to $137.8 million in 2025, then declined by 3.87% to $132.4 million in 2026.
• Per Business Quant, the three latest NVAX Other Accumulated Expenses figures stand at $132.4 million (Q1 2026), $137.8 million (Q4 2025), and $138.3 million (Q3 2025).